# Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)

> **NCT02320474** · PHASE4 · COMPLETED · sponsor: **Poitiers University Hospital** · enrollment: 26 (actual)

## Conditions studied

- Type 3 Choroidal Neovascularization

## Interventions

- **DRUG:** Aflibercept

## Key facts

- **NCT ID:** NCT02320474
- **Lead sponsor:** Poitiers University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-25
- **Primary completion:** 2018-11
- **Final completion:** 2018-11
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2019-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02320474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02320474, "Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02320474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*